Microenvironment of metastatic site reveals key predictors of PD-1 blockade response in renal cell carcinoma
Résumé
Immune checkpoint blockade (ICB) therapies are now an important tool in the arsenal for the treatment of advanced cancer extending progression-free survival and overall survival. However, only a subset of cancer patients responds to ICB therapies causing an urgent need for novel approaches to better select patients who may benefit from immunotherapy. Here, we used metastatic ccRCC samples obtained before ICB treatment and performed cell deconvolution analysis to investigate novel biomarkers of ICB treatment response.